- Tech Only CPT
- Tech Pro CPT 88184, 88189, 88185x24
- PowerPath Code FL DBM
- Schedule Monday - Friday (Weekends by arrangement for clinically urgent Flow diagnostics)
- Turn Around Time 1 Day
- Disease State Anemia, Leukopenia, Neutropenia, Thrombocytopenia
- Methodology Flow Cytometry
Bone Marrow in Heparin or EDTA.
Bone Marrow: 1.0 - 5.0mL
This panel is performed to determine if a lymphoid or myeloid hematologic disorder is the cause of cytopenia(s).
Required Patient Info
1) Requisition form with the patient’s name, DOB, DOC and recent treatments.
2) CBC report for Peripheral Blood.
Storage and Transportation
Bone Marrow : 48-72hrs transport at room temperature.
Cause for Rejection
Specimens without 2 (two) patient identifiers. Incorrect anticoagulant or lack of anticoagulant, frozen or incorrectly stored specimens (i.e., excessive heat or cold), severely hemolyzed specimens (minimal hemolysis will be evaluated on a case-by-case basis), broken or leaking tubes, specimens received with needles affixed, submitted in fixative - no fixative is acceptable!, specimen age: >72 hours for peripheral blood and >5 days for bone marrow *see note below, clotted specimens (small clots are acceptable-others evaluated on a case-by-case basis), contamination (bacterial, fungal, drug interaction, chylous, etc.), incorrectly labeled specimens or insufficient transport media for tissues and FNA’s.
*Note: Peripheral blood specimens >72-hours old are reported on a case-by-case basis and must be approved by the pathologist reviewing the case. Bone marrow specimens >5 days old are reported on a case-by-base basis and must be approved by the pathologist reviewing the case.
These tests were developed and the performance characteristics determined by CellNetix Pathology & Laboratories. They have not been cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This laboratory is certified under CLIA-88 and is qualified to perform high complexity clinical testing. Prognostic and predictive testing should be interpreted in the context of additional clinical and/or histopathological findings.